Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.77), $0.08 worse than the analyst estimate of ($0.69). Revenue for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE